GI Inno "GI-101·GI-102 and Anticancer Drug Combination Therapy, US Patent Registered"

GI Innovation announced on the 15th that U.S. patents have been granted for the immuno-oncology drugs GI-101 and GI-102, as well as for combination therapies with various anticancer agents.

GI Innovation logo. [Image provided by GI Innovation]

The company explained that this patent has been broadly registered for blockbuster anticancer drugs such as PARP (Poly ADP-ribose polymerase) inhibitors, CDK4/6 inhibitors, and VEGFR inhibitors, allowing them to enjoy exclusive rights to combination therapies with various anticancer agents belonging to these categories. Earlier in May, GI Innovation secured exclusive rights in the U.S. through patents on combination therapies of GI-101 or GI-102 with immuno-oncology drugs such as PD-1 antibodies like Keytruda and PD-L1 antibodies like Atezolizumab.

GI Innovation expects that the current anticancer combination therapy patent, which additionally includes PARP inhibitors, CDK4/6 inhibitors, VEGFR inhibitors, and epidermal growth factor receptor (EGFR) inhibitors, will enable comprehensive protection by covering exclusive rights to combination therapies with various anticancer agents. They also added that they could become a partner in the patent term extension strategies of blockbuster anticancer drugs.

According to the global market research firm Research Nester, with the substance patent expiration dates approaching for Abemaciclib (patent expires in 2029), which holds a high market share in the approximately 2.5 trillion KRW global CDK4/6 inhibitor market, and Olaparib (patent expires in 2028), which accounts for the largest sales in the approximately 900 billion KRW PARP inhibitor market, GI Innovation has secured patent terms for combination therapies of GI-101 and GI-102 with these anticancer agents until 2041.

Myeongho Jang, CSO of Clinical Strategy and the inventor of this patent, stated, "Since this U.S. patent registration pertains to combination therapies with blockbuster anticancer drugs whose patents are nearing expiration, we have prepared sufficient value as combination partners with various anticancer agents depending on clinical results." He emphasized, "We will do our best to achieve technology transfer next year through close contact with global pharmaceutical companies."

This content was produced with the assistance of AI translation services.